Does reduced pancreatic lipase activity increase fecal fat and long-chain fatty acids?

The relationship between pancreatic enzyme function and lipid excretion is well-established in clinical physiology, particularly regarding the role of pancreatic lipase in the digestion and absorption of dietary fats.

Clinical and effectiveness evidence

Reduced pancreatic lipase activity is a primary driver of fat malabsorption, a condition clinically characterized by increased total fecal fat and steatorrhea. Research consistently demonstrates that when lipase output falls below approximately 10% of normal capacity, the digestive system can no longer efficiently process dietary triglycerides.

• In healthy individuals, the Coefficient of Fat Absorption (CFA) is typically greater than 93–95%.
• When lipase activity is significantly impaired—as seen in exocrine pancreatic insufficiency (EPI)—the CFA can drop below 70%, leading to significant increases in fecal lipid excretion.
• Diagnostic markers such as fecal elastase-1 (FE-1) levels below 100 µg/g are often used as surrogates for severe lipase deficiency and are strongly correlated with elevated fecal fat.

Mechanistic explanations

Pancreatic lipase is the essential enzyme responsible for hydrolyzing long-chain triglycerides into absorbable 2-monoacylglycerols and free long-chain fatty acids (LCFAs).

• Hydrolysis failure: Reduced lipase activity prevents the breakdown of triglycerides into the smaller components required for micelle formation. Without micelle formation, LCFAs cannot be transported to the enterocyte brush border for absorption.
• Colonic accumulation: Undigested triglycerides and partially digested lipids pass into the colon. While colonic bacteria may perform some secondary hydrolysis of these triglycerides into free fatty acids, the colon lacks the specialized transport mechanisms for efficient LCFA absorption, resulting in their excretion in the stool.
• Validation through intervention: This mechanism is confirmed by pharmacological studies (e.g., using lipase inhibitors like orlistat) and therapeutic interventions where Pancreatic Enzyme Replacement Therapy (PERT) restores lipase activity and subsequently reduces fecal LCFA levels.

Bottom line

Scientific evidence strongly supports the claim that reduced pancreatic lipase activity leads to increased total fecal fat and long-chain fatty acids by disrupting the critical hydrolysis and absorption pathways for dietary triglycerides.